Clinical Trial

Early Neutropenic Fever De-escalation of Antibiotics Study

Study acronym: END
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 26, 2024 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a randomized, open label clinical trial among individuals with hematologic conditions. The trial aims to evaluate the safety and clinical outcomes of de-escalating antibiotic therapy among stable individuals diagnosed with neutropenic fever, in which no bacterial infection has been identified.
Trial Details
NCT Number NCT06278896
Lead Sponsor Brigham and Women's Hospital
Collaborators: Dana-Farber Cancer Institute
Conditions Hematologic Malignancy, Febrile Neutropenia, Antibiotic Stewardship
Enrollment 260 participants
Start Date 2024-03-01
Primary Completion 2026-03-01 (estimated)
Study Completion 2028-03-01 (estimated)
Updated on ClinicalTrials.gov 2024-02-26